Effects of MK-886, an inhibitor of the 5-lipoxygenase-activating protein, on peripheral blood mononuclear cells from patients with Chagas' heart disease.

T. cruzi antigen stimulation significantly increased cytokine production in PBMCs from patients with chronic Chagas disease.

• Cytokines assessed included IFN-γ, IL-13, IL-17, IL-10, and TNF-α
• PBMCs were derived from patients with chronic Chagas heart disease
• Cells were stimulated with T. cruzi antigen in the presence or absence of MK-886
• The antigen-driven cytokine increases served as the baseline against which MK-886 effects were measured

MK-886 significantly reduced IFN-γ, IL-13, and IL-17 production in T. cruzi antigen-stimulated PBMCs from Chagas disease patients.

• MK-886 is described as a 5-lipoxygenase-activating protein (FLAP) inhibitor
• The reductions spanned Th1 (IFN-γ), Th2 (IL-13), and Th17 (IL-17) cytokine profiles
• The reductions were described as statistically significant
• This multi-cytokine suppression suggests broad modulation of T helper cell responses via the leukotriene pathway

MK-886 did not alter IL-10 or TNF-α production in T. cruzi antigen-stimulated PBMCs from Chagas disease patients.

• IL-10 is an anti-inflammatory/regulatory cytokine whose preservation suggests MK-886 does not cause global immunosuppression
• TNF-α, a pro-inflammatory cytokine involved in parasite control, also remained unchanged
• The authors interpreted this selective cytokine modulation as evidence that MK-886 reduces damaging inflammation without inducing immunosuppression

T. cruzi antigen stimulation significantly increased cell death (apoptosis and necrosis) and cell proliferation in PBMCs from chronic Chagas disease patients.

• Both apoptosis and necrosis were measured as distinct forms of cell death
• Cell proliferation was also assessed alongside cell death parameters
• These increases in antigen-stimulated cells provided the context for evaluating MK-886's effects on cellular outcomes

MK-886 treatment markedly reduced apoptosis, necrosis, and proliferation in T. cruzi antigen-stimulated PBMCs from chronic Chagas disease patients.

• Reductions in apoptosis and necrosis suggest a cytoprotective effect of FLAP inhibition
• Reduced cell proliferation may reflect dampened pathological immune activation
• The effects were described as 'markedly reduced' in antigen-stimulated conditions
• These cellular outcomes complement the cytokine findings in supporting an anti-inflammatory role for MK-886

5-Lipoxygenase deficiency has been associated with cardioprotective effects in mouse models of Chagas disease, providing the rationale for testing FLAP inhibition.

• The leukotriene pathway is implicated in modulating immune responses during T. cruzi infection
• Lipid mediators including leukotrienes play a key role in immune modulation during infection
• MK-886 was selected as a pharmacological tool to inhibit the 5-lipoxygenase-activating protein (FLAP)
• The authors proposed that targeting the leukotriene pathway may delay the progression of cardiac damage in Chagas disease

The authors concluded that MK-886 has the potential to reduce tissue-damaging inflammation and fibrosis associated with Th1, Th2, and Th17 responses in Chagas heart disease.

• The reduction in IFN-γ (Th1), IL-13 (Th2), and IL-17 (Th17) was interpreted as evidence of reduced fibrosis-promoting and tissue-damaging inflammation
• Preservation of IL-10 and TNF-α was interpreted as absence of immunosuppression
• The authors suggest targeting the leukotriene pathway 'may delay the progression of cardiac damage in Chagas disease'
• Chagas disease remains a major public health challenge in Latin America, providing clinical relevance for this finding